Beta Cell Regeneration for Diabetes Therapy

The summary for the Beta Cell Regeneration for Diabetes Therapy grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Beta Cell Regeneration for Diabetes Therapy: - The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to characterize the regenerative potential of human beta cells and/or islets in vivo, to identify cellular and molecular components regulating pancreas regeneration in normal and diabetic adults, and to identify mediators and cellular targets with therapeutic potential for enhancing pancreatic regeneration in diabetic patients. It is anticipated that findings will facilitate attempts to slow or reverse tissue damage, and/or enhance recovery of beta cell function in diabetes. - The NIDDK intends to commit approximately $2,000,000 in FY2006 to support this initiative - It is anticipated that 4 to 5 new and/or competing continuation grants will be funded in response to this RFA - Both Investigator-Initiated Research Project Grant (R01) and Exploratory/Development Research Grant (R21) Award mechanisms will be eligible for support under this RFA. - For profit and non-profit organizations are eligible, including public or private institutions, units of state and local governments, eligible agencies of the federal government, domestic or foreign institutions/organizations, and faith-based or community-based organizations. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Investigators may submit more than one application, provided there is no scientific or budgetary overlap. - Applications must be prepared using the PHS 398 research grant application instructions and forms (rev. 09/2004; http://grants.nih.gov/grants/funding/phs398/phs398.html). - Telecommunications for the hearing impaired is available at: TTY 301-451-0088
Federal Grant Title: Beta Cell Regeneration for Diabetes Therapy
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-05-007
Type of Funding: Grant
CFDA Numbers: 93.847
CFDA Descriptions: Diabetes, Endocrinology and Metabolism Research
Current Application Deadline: No deadline provided
Original Application Deadline: Jun 22, 2005
Posted Date: Mar 01, 2005
Creation Date: Mar 01, 2005
Archive Date: Jul 22, 2005
Total Program Funding: $2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 4
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments County governments City or township governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors...
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Requ...
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...
Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
Molecular Therapy Core Centers
Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com